title: [Immunophenotyping characteristics of AML and their correlation with the curative effects].
abstract: This study was aimed to explore the immunophenotyping characteristics of acute myeloid leukemia (AML) and their correlation with the curative efficacy. The bone marrow or blood samples were collected from 516 patients with newly diagnosed AML, and their immunophenotypes were analyzed by flow cytometry. The results showed that (1) In 516 cases, the ratios of myeloid antigen expression were higher, as follows: MPO 95.0%, CD33 93.0%, CD13 88.8%, CD117 69.4%; and the expressions of CD14, CD15, CD64 and CD71 were lower, meanwhile 145 cases were accompanied with lymphocyte antigen expression, the ratios were as follows: CD7 21.5%, CD19 6.0%, CD2 0.78%, CD10 0.58% and CD20 0.58%; the positive expression rate of CD71 in M6 was 100%, and that of CD64 in M5 was the highest (30.2%); the overall positive rate of CD34 was 57.8%. (2) After first chemotherapy, the complete remission (CR) rate was 64.7%, CR rate of CD34(+) patients was lower than that of CD34(-) in M3 group (P = 0.019). The CR rate of CD34(+) patients was significantly lower than that of CD34(-) in non-M3 group (P = 0.002). The CR rate of CD19(+) patients was higher than CD19(-) (P = 0.028); the CR rate of CD7(+) patients was significantly lower than that of CD7(-) (P = 0.002); the CR rate of CD71(+) patients was lower than that of CD71(-) (P = 0.013); the CR rate of MPO(+) patients was higher than that of MPO(-) (P = 0.015). Between the CR rate of CD11b, CD13, CD33-positive and-negative group, the difference was not statistically significant (P > 0.05). It is concluded that the phenotype is a prerequisite for the diagnosis of AML, and can help to guide the clinical typing, selection of treatment protocols and evaluation of prognosis.
authors.affiliation: Department of Hematology, Anhui Provincial Hospital, Hefei 230001,Anhui Province, China.
authors.forename: Lu-Lu
authors.initials: LL
authors.lastname: Yang
authors.affiliation: Department of Hematology, Anhui Provincial Hospital, Hefei 230001,Anhui Province, China. E-mail:lxinahf@sina.com.
authors.forename: Xin
authors.initials: X
authors.lastname: Liu
authors.affiliation: Central Laboratory, Provincial Hospital Affiliated to Anhui Medical University,Anhui Provincial Hospital, Hefei 230001,Anhui Province, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
authors.affiliation: Department of Hematology, Anhui Provincial Hospital, Hefei 230001,Anhui Province, China.
authors.forename: Xiao-Yu
authors.initials: XY
authors.lastname: Zhu
authors.affiliation: Department of Hematology, Anhui Provincial Hospital, Hefei 230001,Anhui Province, China.
authors.forename: Xing-Bing
authors.initials: XB
authors.lastname: Wang
authors.affiliation: Department of Hematology, Anhui Provincial Hospital, Hefei 230001,Anhui Province, China.
authors.forename: Wei-Bo
authors.initials: WB
authors.lastname: Zhu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000235:genetics; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D015703:Antigens, CD